Építés alatt – nem éles oldal
Belépés
Befejeződött3. fázis

Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)

A legfontosabb adatok

Ki végzi
Duke University
Hol
Aurora, Boston, Chapel Hill, Cincinnati, Cleveland, Columbus, Gainesville, Hackensack, Indianapolis, Iowa City, Louisville, Minneapolis, Nashville, Philadelphia, Rochester, Salt Lake City, San Francisco, Seattle és The Bronx (Egyesült Államok)Mind a 19 helyszín megnézése
Azonosító
Állapot
Befejeződött
Fázis
3. fázis
Résztvevők
121 fő vett részt
Kezdés
2019. okt. 29.
Befejezés
2025. jan. 22.
A vizsgálat típusa
Beavatkozással járó, 4 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Abatacept Injection
  • Usual Care
A regiszteradat frissítve
2026. január 23.

Ki vehet részt

Életkor
2 év – 16 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 30 feltétel megnézéseKevesebb

Egyéb feltételek

  • To be eligible for this trial, participants must meet all of the following criteria in order to be include in the study:
  • Age ≥ 2 years old and ≤16.5 years old
  • Clinical diagnosis of JIA by a pediatric rheumatologist within the past 6 months
  • Arthritis affecting ≤4 joints between disease onset and enrollment
  • Enrollment in the CARRA Registry
  • Participants of childbearing potential must agree to remain abstinent or agree to use an effective and medically acceptable form of birth control from the time of written or verbal assent to at least 66 days after taking the last dose of study drug
  • Weight ≥50 kg (Canadian Sites only) ¹ Enrollment is defined as having signed consent to participate in the Limit-JIA study; The presence of any of the following will exclude a study participant from inclusion in the study:
  • 1. Systemic JIA as defined by 2004 ILAR criteria1
  • Sacroiliitis (clinical or radiographic)
  • Inflammatory bowel disease (IBD)
  • History of psoriasis or currently active psoriasis
  • History of uveitis or currently active uveitis
  • Prior treatment with systemic medication(s) for JIA (e.g. one or more of the following: DMARD or biologic medication)
  • Current or previous (within 30 days of enrollment) treatment with systemic glucocorticoids (A short course of oral prednisone [≤ 14 days] is allowed)
  • History of active or chronic liver disease
  • Chronic or acute renal disorder
  • AST (SGOT), ALT (SGPT) or BUN >2 x ULN (upper limit of normal) or creatinine >1.5 mg/dL or any other laboratory abnormality considered by the examining physician to be clinically significant within 2 months of the enrollment visit
  • Presence of any medical or psychological condition or laboratory result which would make the participant, in the opinion of the investigator, unsuitable for the study
  • Participation in another concurrent clinical interventional study within 30 days of enrollment
  • Known positive human immunodeficiency virus (HIV)
  • Received a live virus vaccine within 1 month of the baseline visit
  • Current or prior positive Purified Protein Derivative (PPD) test or Quantiferon Gold TB
  • Pregnant, breast feeding, or planned breast feeding during the study duration
  • Planned transfer to non-participating pediatric rheumatology center or adult rheumatologist in the next 12 months
  • Active malignancy of any type or history of malignancy
  • Chronic or active infection or any major episode of infection requiring hospitalization or treatment with intravenous (IV) antibiotics within 30 days or oral antibiotics within 14 days prior to screening
  • Primary language other than English or Spanish
  • Positive for Hepatitis B surface antigen or core antibody
  • <10 Kg in weight
  • If a potential subject has symptoms consistent with COVID-19 and/or known COVID-19 exposure at screening, it is recommended that the site follow CDC guidance regarding testing and quarantine requirements. The subject can be re-screened when there is no longer concern for active infection. A subject with a positive COVID -19 test may be re-screened

Helyszínek itt: Egyesült Államok

  • The Children's Hospital ColoradoAurora, Egyesült Államok
  • Boston Children's HospitalBoston, Egyesült Államok
  • University of North CarolinaChapel Hill, Egyesült Államok
  • Cincinnati Children's Hospital Medical CenterCincinnati, Egyesült Államok
  • MetroHealth SystemCleveland, Egyesült Államok
  • Nationwide Children's HospitalColumbus, Egyesült Államok
  • Shands at the University of FloridaGainesville, Egyesült Államok
  • Hackensack University Medical CenterHackensack, Egyesült Államok
  • Riley Hospital for Children at Indiana University HealthIndianapolis, Egyesült Államok
  • University of Iowa Hospitals of ClinicsIowa City, Egyesült Államok
  • University of Louisville School of Medicine/ Norton Charities Pediatric Clinical Research UnitLouisville, Egyesült Államok
  • University of Minnesota; Children's Hospital and Clinics of MinnesotaMinneapolis, Egyesült Államok
  • Monroe Carell Jr. Children's Hospital at VanderbiltNashville, Egyesült Államok
  • Children's Hospital of PhiladelphiaPhiladelphia, Egyesült Államok
  • Mayo ClinicRochester, Egyesült Államok
  • University of UtahSalt Lake City, Egyesült Államok
  • University of California at San Francisco Medical CenterSan Francisco, Egyesült Államok
  • Seattle Children's HospitalSeattle, Egyesült Államok
  • Children's Hospital at Montefiore/ Albert Einstein University HospitalThe Bronx, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a research study to test whether a once-weekly injection of abatacept will prevent the progression of Juvenile Idiopathic Arthritis (JIA) to a more severe form. To evaluate the effectiveness of a 24-week course of treatment with abatacept plus usual care versus usual care to prevent polyarthritis (≥5 joints), uveitis, or treatment with other systemic medication within 18 months of randomization in children with recent-onset limited JIA.

A vizsgálat 4 csoportja

  • Abatacept and Usual Care (Part I)A vizsgált kezelés

    Weekly abatacept injection at standard dosing for weight plus usual care with steroid joint injection and non-steroidal anti-inflammatory drugs per the discretion of the treating provider.

    Kezelés: Abatacept Injection és Usual Care

  • Active Comparator: Usual Care (Part I)Már használt kezelés, összehasonlításként

    Usual care includes steroid joint injections and treatment with non-steroidal anti-inflammatory drugs at the discretion of the treating provider.

    Kezelés: Usual Care

  • Abatacept and Usual Care (Part II)A vizsgált kezelés

    Weekly abatacept injection at standard dosing for weight plus usual care with steroid joint injection and non-steroidal anti-inflammatory drugs per the discretion of the treating provider.

    Kezelés: Abatacept Injection és Usual Care

  • Active Comparator: Usual Care (Part II)Már használt kezelés, összehasonlításként

    Usual care includes steroid joint injections and treatment with non-steroidal anti-inflammatory drugs at the discretion of the treating provider.

    Kezelés: Usual Care

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
An Open Label, Multi-Center, Phase 3 Efficacy Study of Sub-Q Abatacept in Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)
A regiszteradat frissítve
2026. január 23.